About Biopharmx Corp (NYSEAMERICAN:BPMX)
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women's health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia. Its VI2OLET is an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort and is clinically demonstrated to alleviate the symptoms associated with FBC, including tenderness, aches and swelling. It is developing BPX02, which is an injectable utilizing biologic materials for aesthetic dermatology applications.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
SectorBio Therapeutic Drugs
SymbolNYSEAMERICAN:BPMXPrevious Symbol: NYSE:BPMX
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-5,749.08%
Return on Assets-240.31%
Frequently Asked Questions for Biopharmx Corp (NYSEAMERICAN:BPMX)
What is Biopharmx Corp's stock symbol?
Biopharmx Corp trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BPMX."
How were Biopharmx Corp's earnings last quarter?
Biopharmx Corp (NYSEAMERICAN:BPMX) posted its quarterly earnings results on Wednesday, September, 13th. The biotechnology company reported ($0.06) earnings per share for the quarter, hitting the consensus estimate of ($0.06). The biotechnology company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.02 million. Biopharmx Corp had a negative return on equity of 5,749.08% and a negative net margin of 22,005.88%. View Biopharmx Corp's Earnings History.
When will Biopharmx Corp make its next earnings announcement?
Where is Biopharmx Corp's stock going? Where will Biopharmx Corp's stock price be in 2017?
3 Wall Street analysts have issued 12 month price targets for Biopharmx Corp's stock. Their predictions range from $1.50 to $3.00. On average, they expect Biopharmx Corp's share price to reach $2.50 in the next year. View Analyst Ratings for Biopharmx Corp.
Are investors shorting Biopharmx Corp?
Biopharmx Corp saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 4,599,284 shares, an increase of 7.7% from the October 13th total of 4,271,767 shares. Based on an average daily trading volume, of 1,541,571 shares, the short-interest ratio is presently 3.0 days. Currently, 8.0% of the shares of the stock are short sold.
Who are some of Biopharmx Corp's key competitors?
Some companies that are related to Biopharmx Corp include Xenetic Biosciences (XBIO), Cerulean Pharma (DARE), Ritter Pharmaceuticals (RTTR), Heat Biologics (HTBX), Proteome Sciences plc (PRM), Evgen Pharma plc (EVG), Bio Blast Pharma (ORPN), ValiRx Plc (VAL), Ariad Pharmaceuticals (ARIA), Cynapsus Therapeutics (CYNA), Dyax Corp. (DYAX), Kythera Biopharmaceuticals (KYTH), Ocata Therapeutics (OCAT), Receptos (RCPT), Relypsa (RLYP), Tobira Development (TBRA) and ZS Pharma (ZSPH).
Who are Biopharmx Corp's key executives?
Biopharmx Corp's management team includes the folowing people:
- James R. Pekarsky, Chairman of the Board, Chief Executive Officer (Age 55)
- Anja B. Krammer, President, Director (Age 47)
- Gregory David Kitchener, Chief Financial Officer, Executive Vice President - Finance
- Kin F. Chan Ph.D., Executive Vice President - Research & Development (Age 41)
- AnnaMarie Daniels, Executive Vice President - Clinical and Regulatory Affairs
- Stephen Morlock, Independent Director (Age 61)
- Charles Gregory Vontz, Independent Director (Age 55)
- Ping Wang, Independent Director (Age 38)
How do I buy Biopharmx Corp stock?
Shares of Biopharmx Corp can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biopharmx Corp's stock price today?
One share of Biopharmx Corp stock can currently be purchased for approximately $0.12.
How big of a company is Biopharmx Corp?
Biopharmx Corp has a market capitalization of $9.96 million.
How can I contact Biopharmx Corp?
Biopharmx Corp's mailing address is 1505 Adams Dr Ste D, MENLO PARK, CA 94025-1451, United States. The biotechnology company can be reached via phone at +1-650-8895020.
MarketBeat Community Rating for Biopharmx Corp (BPMX)MarketBeat's community ratings are surveys of what our community members think about Biopharmx Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Biopharmx Corp (NYSEAMERICAN:BPMX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 3 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$2.50|
Consensus Price Target History for Biopharmx Corp (NYSEAMERICAN:BPMX)
Analysts' Ratings History for Biopharmx Corp (NYSEAMERICAN:BPMX)
(Data available from 11/23/2015 forward)
|9/19/2017||HC Wainwright||Reiterated Rating||Buy||$3.00|
|9/13/2017||Maxim Group||Lower Price Target||Buy||$3.00 -> $1.50|
|6/3/2017||Roth Capital||Set Price Target||Buy||$3.00|
Earnings History and Estimates Chart for Biopharmx Corp (NYSEAMERICAN:BPMX)
Earnings History by Quarter for Biopharmx Corp (NYSEAMERICAN BPMX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|12/12/2017|| || || || || || || || |
|9/13/2017||Q2 2018||($0.06)||($0.06)||$0.02 million||$0.02 million||View||N/A|
|6/13/2017||Q1 2018||($0.07)||($0.07)||$0.03 million||$0.02 million||View||N/A|
Earnings Estimates for Biopharmx Corp (NYSEAMERICAN:BPMX)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Biopharmx Corp (NYSEAMERICAN:BPMX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Biopharmx Corp (NYSEAMERICAN BPMX)
Insider Trades by Quarter for Biopharmx Corp (NYSEAMERICAN BPMX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/9/2017||Vivo Capital Viii, Llc||Major Shareholder||Sell||296,394||$0.20||$59,278.80|| |
|8/1/2017||Franklin Resources Inc||Major Shareholder||Buy||250,000||$0.34||$85,000.00|| |
|4/28/2017||Vivo Capital Fund Viii, L.P.||Major Shareholder||Buy||1,282,052||$0.78||$1,000,000.56|| |
|11/28/2016||Stephen Morlock||Director||Buy||428,571||$0.35||$149,999.85|| |
|8/15/2016||Franklin Resources Inc||Major Shareholder||Buy||484,615||$0.65||$314,999.75|| |
|3/29/2016||Franklin Resources Inc||Major Shareholder||Buy||540,000||$1.20||$648,000.00|| |
|1/14/2016||Stephen Morlock||Director||Buy||12,000||$1.52||$18,240.00|| |
|1/12/2016||Stephen Morlock||Director||Buy||6,000||$1.53||$9,180.00|| |
|1/7/2016||Stephen Morlock||Director||Buy||5,000||$1.47||$7,350.00|| |
|10/15/2015||Stephen Morlock||Director||Buy||5,000||$1.24||$6,200.00|| |
|10/9/2015||Stephen Morlock||Director||Buy||3,000||$1.21||$3,630.00|| |
Latest Headlines for Biopharmx Corp (NYSEAMERICAN BPMX)
Biopharmx Corp (NYSEAMERICAN BPMX) Chart for Thursday, November, 23, 2017